Thu Sep 29 12:56:22 SGT 2016  
SINGAPORE
SEXUALHEALTH™
    Genital Warts
SINGAPORE SEXUALHEALTH™
HIV PEP (post-exposure prophylaxis): Stop HIV infection within 3 days after unprotected sex.
HIV test: 20 minute rapid test to accurately detect HIV infection 28 days after unprotected sex.
STD testing: Full & comprehensive sexually transmitted disease testing.

Genital Warts | SINGAPORE SEXUALHEALTH™

Summary

Genital Warts | SINGAPORE SEXUALHEALTH™ @singaporesexualhealth_com: Genital warts, Singapore. Private & confidential service.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
SINGAPORE SEXUALHEALTH™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: www.shimclinic.com
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Description

Table of Contents

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Warts - on male sex organ Genital warts appear within 3 months after sexual contact with an infected person.

Genital warts:

  • are usually soft, pink cauliflower-like growths or flesh-coloured bumps on the sex organs
  • may also be hard and smooth
  • occur alone or in groups
  • tend to recur after treatment
  • increase the risk of cervical cancer in women.


Warts - on female sex organ An infected woman may infect her newborn during childbirth.

A person with genital warts can infect others through sexual contact.



Genital warts treatment / HPV treatment

HPV / human papillomavirus.

  • 120 known human papillomavirus (HPV)
  • 51 HPV types, and 3 subtypes are genital HPV as they infect the genital mucosa.
  • 31 genital HPV types are low risk
  • 6 genital HPV types are intermediate risk
  • 17 genital HPV types are high risk
They cause Genital HPV types, cancer risk, vaccine and test coverage
Type
Species
Risk
Cervarix
Gardasil
Gardasil-9
DigeneHR
DigenePS
CobasHPV
Digene
HybriBio
PapilloCheck
InnoLiPA
LinearArray
61 3 L ----------+-
72 3 L ----------+-
81 3 L -------+--+-
83 3 L ----------+-
84 3 L ----------+-
62 3 L ----------+-
CP6108 3 L ----------+-
71 15 L ---------++-
26 5 H ---------++-
51 5 H ---+-++++++-
69 5 H ---------++-
82 5 H --------+++-
IS39 5 H ----------+-
18 7 H +++++++++++-
39 7 H ---+-++++++-
45 7 H --+++++++++-
59 7 H ---+-++++++-
68 7 H ---+-++++++-
70 7 H --------+++-
53 6 H -------++++-
56 6 H ---+-++++++-
66 6 H -----+-++++-
54 13 L ---------++-
42 1 L ------+++-+-
40 8 L --------+++-
43 8 L ------++++--
6 10 L -++---+++++-
11 10 L -++---+++++-
44 10 L ------++++--
74 10 L ---------+--
16 9 H +++++++++++-
31 9 H --++-++++++-
33 9 H --++-++++++-
35 9 H ---+-++++++-
52 9 H --++-++++++-
58 9 H --++-++++++-
67 9 H ----------+-
73 11 H --------+++-

Legend: 71 (CP 8061), 73/MM9, 81 (CP 8304), 82 (MM4), 82 (IS 39), 83 (MM7), 84 (MM8), 89 (CP 6108)

References

Cervical cancer HPV vaccine (previously known as cervical cancer vaccine) types:
  • Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
  • Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant]
  • V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant]
References Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] References Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant] References V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant] - to be released in 2013 STD vaccine / hepatitis vaccine shot/jab/injection to prevent some STDs

Vaccine Against Disease Age D
o
s
e
s
Dose schedule Price
per
dose
(SG$)
Havrix™ 1440 Adult Hepatitis A virus Hepatitis A ≥19y 2 m 0 & 6-12 $90/=
Twinrix® Hepatitis A virus
Hepatitis B virus
Hepatitis A
Hepatitis B
1-15y 2 m 0, 6-12 $135/=
≥16y 3 m 0, 1, 6
4 d 0, 7, 21 & m 12
Inactivated / Fractional / Protein / Subunit / Recombinant
Engerix™-B 20 μg Hepatitis B virus Hepatitis B 11-15y 2 m 0, & 6 $50/=
≥20y 3 m 0, 1, & 6
4 m 0, 1, 2, & 12 or
d 0, 7, 21 & m 12
Gardasil® HPV
types 6, 11, 16, & 18
Genital warts
Cervical cancer
9-26y 3 m 0, 2, & 6 or
m 0, 1, & 4
$195/=
Cervarix® HPV
types 16, & 18
(31, 33, & 45)
10-25y 3 m 0, 1, & 6
m 0, 1, & 5
m 0, 2½, 12
$195/=
V503 HPV
types 6, 11, 16, 18,
31, 33, 45,
52, & 58
3 m 0, 2, & 6 or
m 0, 1, & 4
$???/=

HPV test for men/women.

  • Digene® High-Risk HPV DNA Test
  • Digene® HPV DNA Test
  • Digene® HPV Genotyping PS Test
  • Hybribio®
    • HPV GenoArray Test Kit
    • Detects 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68. And 6 low-risk HPV types: 6, 11, 42, 43, 44, CP8304
    • Able to differentiate which types are positive.
    • May be available in Singapore soon.
  • Cobas® HPV Test
    • Cobas® HPV Test
    • Detects 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
    • The test specifically identifies (types) HPV 16 and HPV 18, while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
    • Cost is SG$200/=
  • LINEAR ARRAY® HPV Genotyping Test
    • LINEAR ARRAY® HPV Genotyping Test
    • Identifies 37 high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 (MM9), 82 (MM4) low-risk HPV genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83 (MM7), 84 (MM8), IS39, and CP6108
  • INNO-LiPA HPV Genotyping Extra
    • INNO-LiPA HPV Genotyping Extra
    • Identifies 15 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) 3 probable high-risk HPV genotypes (26, 53, 66) 7 low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).
  • PapilloCheck®
    • PapilloCheck®
    • Identifies 24 hiv-risk HPV types 16 18 31 33 35 39 45 51 52 53 56 58 59 66 68 70 73 82 and low-risk HPV types 6 11 40 42 43 44

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception (females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing.
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception (females only)
2 weeks HIV DNA PCR test
1 month 20 minute rapid HIV test - SD Bioline HIV Ag/Ab Combo:
- Fingerprick blood sampling.
3 months 20 minute rapid HIV test - OraQuick®:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Global challenges of implementing human papillomavirus vaccines
Tue, 29 Mar 2016 09:23:40 +0100 | International Journal of Infectious Diseases
Abstract: Every year cervical cancer affects around 528000 women and causes 266000 deaths worldwide with 80% of deaths occurring in less developed countries with a concomitant 18-fold difference in mortality occurring between developed and developing countries. Cervical cancers is caused by the Human Papilloma Virus (HPV) with the oncogenic types 16 and 18 accounting for 70% of invasive disease. Other cancers associated with HPV infection include vaginal, vulvar, penile, oropharyngeal and anal cancers. (Source: International Journal of Infectious Diseases)

Factors associated with Ano-genital warts occurrence among Human Immunodeficiency Virus (HIV) infected patients in Gauteng, South Africa
Tue, 29 Mar 2016 09:23:38 +0100 | International Journal of Infectious Diseases
Background: The study highlighted factors associated with the occurrence of ano-genital warts (AGWs) among HIV infected individuals in South Africa (SA). Human Papilloma Virus (HPV) infection occurs more frequently among HIV infected individuals because of their compromised immuno-status. (Source: International Journal of Infectious Diseases)

The epidemiological survey of HPV infection in married women referring to Firoozgar Hospital
Tue, 29 Mar 2016 09:23:38 +0100 | International Journal of Infectious Diseases
Background: The human papillomavirus (HPV) is the main cause of cervical cancer in developing countries. HPV is common in all socioeconomic groups and is spread all over the world. There are more than 100 types of HPV which are divided into high risk and low risk groups. Molecular method is one of the rapid and accurate methods to study HPV genotypes. (Source: International Journal of Infectious Diseases)

Identification of human papillomavirus types causing lesions in penile canerous, pre-cancerous and benign lesions using laser microdissection
Tue, 29 Mar 2016 09:23:35 +0100 | International Journal of Infectious Diseases
Background: Almost half of penile cancers and the majority of penile warts are associated with the two HR types (HPV 16 and HPV 18) and two LR HPV types (HPV 6 and HPV 11), respectively. It is therefore important to document the burden HPV associated diseases of the penis and identify the HPV types associated with the diseases. HPV E6 and E7 mRNA detection is the best indicator of HPV status that is clinically relevant as it indicate transcriptionally active HR HPV infection in lesions. In HR HPV infection an increase in E6 and E7 mRNA expression causes an overexpression of p16INK4A and thus used as a cellular correlate of the increased expression of HR HPV E6 and E7 mRNA in cervical samples. (Source: International Journal of Infectious Diseases)

Assessment of Human Papillomavirus (HPV) type 16 and 18 status by nested multiplex PCR in cervical cancer patients and in healthy women from a tertiary care hospital
Tue, 29 Mar 2016 09:23:35 +0100 | International Journal of Infectious Diseases
Background: Cervical cancer is the most common malignancy in Indian women and approximately 130,000 women fall prey to cervical cancer every year. HPV DNA testing can be used as an adjunct to cytological screening of cervical samples of above 30 year old women and can be used as an optional test for follow-up in women who have slightly abnormal Pap test results. The aim of the study was to assess the HPV 16 and 18 status in cervical cancer patients and in healthy women visiting JIPMER, Pondicherry. (Source: International Journal of Infectious Diseases)

Universal HPV Vaccination of Girls Prevents Genital Warts in Young MenUniversal HPV Vaccination of Girls Prevents Genital Warts in Young Men
Mon, 28 Mar 2016 19:39:01 +0100 | Medscape Medical News Headlines
In Denmark, the human papillomavirus (HPV) vaccination program for girls and women has been followed by a decreased incidence of genital warts in young men. Reuters Health Information (Source: Medscape Medical News Headlines)

Influence of Gender and Gender-Specific Recommendations on Adolescent Human Papillomavirus Vaccination
Sun, 27 Mar 2016 22:00:00 +0100 | American Journal of Preventive Medicine
Conclusions Changing HPV vaccine recommendations had minimal cross-gender impact. Early adoption and timely completion patterns were mostly similar across genders. (Source: American Journal of Preventive Medicine)

Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx
Sun, 27 Mar 2016 22:00:00 +0100 | Oral Oncology
Squamous cell carcinoma of the oropharynx (SCCOP) is a subtype of squamous cell carcinoma of the head and neck (SCCHN) [1]. In the U.S., approximately 13,510 new cases of SCCOP are diagnosed, and 2330 deaths result from these cancers, annually [2]. Although tobacco smoking and alcohol consumption remain significant risk factors for SCCOP, human papillomavirus (HPV) accounts for a growing proportion of cases, particularly in young adults [1,3]. There are more than 100 different HPV types; about 20 of these have oncogenic potential (i.e., the high-risk types) [4]. (Source: Oral Oncology)

Risk factors associated with incident sexually transmitted infections in HIV‐positive patients in the Australian HIV Observational Database: a prospective cohort study
Sun, 27 Mar 2016 22:00:00 +0100 | HIV Medicine
ConclusionsIn this cohort of individualsbeing treated with antiretroviral drugs, those who were MSM, who were 30–39 years old, and who had a prior history of STI, were at highest risk of a further STI diagnosis. (Source: HIV Medicine)

Lifelong widespread warts associated with human papillomavirus type 70/85: a new diagnostic entity?
Sun, 27 Mar 2016 12:33:04 +0100 | Acta Dermatovenerologica Alpina, Panonica, et Adriatica
We present a patient with HPV 70/85-positive widespread cutaneous warts characterized by clinical and histological features atypical for classic generalized verrucosis or epidermodysplasia verruciformis. The cutaneous HPV infection is characterized by verrucous papules or plaques variable in size, number, and distribution depending on the genotype of HPV involved and the immune status of the patient. Human papillomaviruses comprise five genera (alpha, beta, gamma, mu, and nu papillomavirus) with different life-cycle characteristics, epithelial tropisms, and disease associations. Epidermodysplasia verruciformis (EV) is a rare, lifelong, autosomal recessive skin disease characterized by persistent cutaneous human papillomavirus infection not necessarily associated with immune system defects...